National Comprehensive Cancer Network®

USER GUIDE

NCCN Imaging Appropriate Use Criteria

(NCCN Imaging AUC™)

Access to the NCCN Imaging AUC™ is free.

Prior to accessing NCCN Imaging AUC™ users must accept an End-User License Agreement (EULA) and create a free account or login with an existing account on NCCN.org.

About NCCN Imaging AUC™

NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) include information designed to support clinical decision-making around the use of imaging in patients with cancer and are based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

NCCN Imaging AUC™ include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance. Additional information includes the indication, imaging modality, and frequency of use, as well as clinical notes related to the specific recommendation. NCCN Imaging AUC™ also document information on disease stage and histology. All imaging procedures recommended in the NCCN Guidelines®, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT) and ultrasound, are included within NCCN Imaging AUC™.

NCCN Imaging AUC™ are accessible through an easy to use web-based user interface. The NCCN Imaging AUC™ include a full complement of imaging AUC in oncology care. NCCN, a CMS-approved Provider Led Entity (PLE), is committed to assuring that the most up-to-date recommendations are available and reviews and updates NCCN Imaging AUC™ on a continual basis to ensure that the recommendations take into account the most current evidence.

NCCN.org/imagingAUC

1 The top menu of the NCCN Imaging AUC™ contains various drop-down lists for displaying the database (left) and various sorting fields (right).



By default, the data table selects fields for Stage, Imaging Notes, and Guideline Page. You can customize your display by checking/unchecking the data fields boxes. Or check Display All to view data for all available fields.

2 To display the AUC of your choice, select either an NCCN Guideline or Clinical Setting to match your interest. You can further filter by Imaging Modality, Test Purpose, or ICD-10 Code.





Only the Modalities or Testing Purposes recommended for a given disease will be available in the drop down menu.

3 When first selecting a disease or resetting the filters, the data table will display certain default data fields, including: Clinical Setting, Guideline Page, Category of Evidence, Stage, Indication, Imaging Recommendation, Purpose, and Notes. With sorting fields applied, the data table displays the selected NCCN Imaging AUC™.



Clinical Setting	Guideline Page	Category of Evidence	Stage	Indication	Imaging Recommendation	Purpose	Imaging Notes
Inflammatory Breast Cancer	IBC-1	2A		Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup	• Diagnostic bilateral mammogram • Ultrasound as necessary • Breast MRI with contrast (optional) • Chest diagnostic CT with contrast • Bone scan • FDG PET/CT (optional)	Diagnostic	Chest diagnostic CT if pulmonary symptoms present. Breast M exams are performed with IV contrast and require a dedicated breast coil and breast imaging radiologists familiar with the optimal timing sequences and other technical details for image interpretation. Breast MRI may be used for staging evaluation define extent of cancer or presence of multifocal or multicentri cancer in the ipsilateral breast, or as screening of the contralateral breast cancer at time of initial diagnosis (categor 2B). There are no high-level data to demonstrate that the use MRI to facilitate local therapy decision-making improves local recurrence or survival. Breast... read more...
Inflammatory Breast Cancer	IBC-1	2B		Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup	• Sodium fluoride (^{18}F-NaF) PET/CT	Diagnostic	If FDG PET/CT is performed and clearly indicates bone metastasis, bone scan or sodium fluoride PET/CT may not be

4

NCCN Imaging AUC™ are built on a responsive platform that can be viewed on mobile devices. If the screen size cannot accommodate all data fields simultaneously, the interface will automatically hide certain fields and indicate this with a red numbered icon in the left most column of the data table.

An easy-to-read view of the selected AUC can be made available for printing or saving as a PDF by checking the box in the left most column.

A red numbered icon indicates hidden fields when viewed on mobile devices, tablets, or reduced screen sizes. Click on the icon to view additional fields in a vertical display.

Depending on the web browser, the Guideline Page hyperlink will redirect to either the exact NCCN Guidelines page for that recommendation (Internet Explorer, Safari), or to the front page of the NCCN Guidelines (Google Chrome, Firefox) where users can navigate to the appropriate page.



Filters: *Breast Cancer v.4.2018* › *Breast Cancer - Inflammatory Breast Cancer* › *Diagnostic/Staging*

Default Sort | Showing 1 to 2 of 2 entries | Search:

	Clinical Setting	Guideline Page	Category of Evidence	Stage	Indication	Imaging Recommendation	Purpose
	Inflammatory Breast Cancer	IBC-1	2A		Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup	• Diagnostic bilateral mammogram	Diagnostic
					inflammatory breast cancer; Initial workup	NaF) PET/CT • Chest/Abdominal/Pelvic diagnostic CT with contrast	

5

With the desired AUC displayed, individual or multiple records may be selected for printing by checking the printer icon box (left most data field, above). The recommendation is separated into Disease Information and Imaging Recommendation. Print the page or save the record as a PDF.



National Comprehensive Cancer Network®

NCCN Imaging Appropriate Use Criteria™

Disease Information	
Guideline Name:	Breast Cancer
Clinical Setting:	Inflammatory Breast Cancer
Stage:	AJCC, 8th Edition
Indication:	Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup
Guideline Page:	IBC-1

Imaging Recommendation	
Category of Evidence:	2A
Purpose:	Diagnostic
Modality:	• Diagnostic bilateral mammogram • Ultrasound as necessary • Breast MRI with contrast (optional) • Chest diagnostic CT with contrast • Bone scan • FDG PET/CT (optional)
Notes:	Chest diagnostic CT if pulmonary symptoms present. Breast MRI exams are performed with IV contrast and require a dedicated breast coil and breast imaging radiologists familiar with the optimal timing sequences and other technical details for image interpretation. Breast MRI may be used for staging evaluation to define extent of cancer or presence of multifocal or multicentric cancer in the ipsilateral breast, or as screening of the contralateral breast cancer at time of initial diagnosis (category 2B). There are no high-level data to demonstrate that the use of MRI to facilitate local therapy decision-making improves local recurrence or survival. Breast MRI may be helpful for breast cancer evaluation before and after preoperative systemic therapy to define extent of disease, response to treatment, and potential for breast-conserving therapy. False-positive findings on breast MRI are common. If FDG PET/CT is performed and clearly indicates bone metastasis, bone scan or sodium fluoride PET/CT may not be needed. FDG PET/CT can be performed at the same time as diagnostic CT. FDG PET/CT is most helpful in situations where standard staging studies are equivocal or suspicious, especially in the setting of locally advanced or metastatic disease. FDG PET/CT may also be helpful in identifying unsuspected regional nodal disease and/or distant metastases in locally advanced breast cancer when used in addition to standard staging studies.
ICD10:	C50.911, C50.912, C50.919, C50.921, C50.922, C50.929